Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Manage my Boston Scientific account

Quick Links

Contact a representative Online education and training Order products online Reimbursement resources Return a product Customer support

Call customer care

1 (888) 272-1001

SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

SENIOR* Trial – Shortened DAPT** Regimen, Elderly Patients and SYNERGY Bioabsorbable Polymer (BP) Stent

SENIOR Trial is studying 1-month DAPT in stable elderly patients and 6-month DAPT in unstable elderly patients undergoing PCI with the SYNERGY BP-DES or REBEL™ BMS. 

Fast Facts Sign Up
icon_document.png

Indications, Safety, and Warnings

 icon-send-questions.png

Frequently Asked Questions

 icon-contact-email

Request a Sales Rep

Trial Design

Multicenter, randomized trial studying 1,200 patients age 75 or older with coronary artery disease; 596 received a SYNERGY BP-DES and 605 received a REBEL BMS.
 

Nearly identical DAPT duration in both arms of the study1

Nearly identical DAPT duration in both arms of the study
 

Safety and Primary endpoint: MACCE at 12 months data

The SYNERGY BP-DES showed Superior results versus REBEL BMS in elderly patients that received a shortened DAPT regimen in the SENIOR Trial at 12 months1

All Patients

  • 29% reduction in MACCE with SYNERGY BP-DES1
  • 70% reduction (More than 3X reduction) in ID-TLR with SYNERGY BP-DES1
  • The SYNERGY BP-DES continued to show exceptionally low ARC Def/Prob stent thrombosis (ST) rate of 0.5% (versus 1.4% with BMS, p=0.13)1

1-Month DAPT Discontinuation Cohort

  • More than 50% of patients received 1-month DAPT
  • Zero ST with SYNERGY BP-DES after patient stopped DAPT at 1-month through 12-months1
  • 34% reduction in MACCE with SYNERGY BP-DES2
  • 90% reduction (More than 10X reduction) in ID-TLR with SYNERGY BP-DES2
SENIOR Trial Safety Data with SYNERGY BP-DES in 1-Month DAPT Cohort - Primary Endpoint: MACCE at 12-months
 

Safety and MACCE at 2-Year data

SYNERGY BP-DES showed statistically significant reduction in ID-TLR compared to REBEL BMS at 2-Years3

All Patients

  • 65% reduction (Nearly 3X reduction) in ID-TLR with SYNERGY BP-DES
  • The SYNERGY BP-DES continued to show low ARC Def/Prob stent thrombosis (ST) rate of 0.7% (versus 1.4% with BMS, p=0.28)
Safety Endpoints at 12-months

1-Month DAPT Discontinuation Cohort

  • 79% reduction (More than 4.5X reduction) in ID-TLR with SYNERGY BP-DES
  • The SYNERGY BP-DES continued to show exceptionally low ARC Def/Prob stent thrombosis (ST) rate of 0.6% (versus 1.4% with BMS, p=0.32)
1-Month DAPT Discontinuation Cohort
Clinical Outcomes

Clinical Outcomes

Outstanding evidence across trials

Button
Real-World Studies

Real-World Studies

Low event rates in real-world studies

Button
Early Healing

Early Healing

Advanced design for optimal healing

Button
Top